Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation

• Published in: Clinical cardiology (Mahwah, N.J.) N.J.), 2022-04, Vol.45 (4), p.447-456
• Main Authors: Krittayaphong, Rungroj, Pumprueg, Satchana, Sairat, Poom
• Format: Article
• Language: English
• Subjects: Aged; Anemia; Atrial Fibrillation - diagnosis; Biomarkers; Cardiac arrhythmia; Cardiology; Cardiovascular disease; Clinical Investigations; Clinical outcomes; Confidence intervals; Coronary vessels; Diabetes; Electrocardiography; Female; Heart failure; Heart Failure - diagnosis; history of heart failure; Humans; Hypertension; Immunoassay; Interleukin-1 Receptor-Like 1 Protein; Kidney diseases; Laboratories; Male; Medical prognosis; Middle Aged; Natriuretic Peptide, Brain; nonvalvular atrial fibrillation; Patients; Peptide Fragments; Peptides; Prognosis; prognostic significance; Prospective Studies; soluble ST2 level; Stroke
• ISSN: 0160-9289; 1932-8737
• DOI: 10.1002/clc.23799

Background Biomarkers may be a useful marker for predicting heart failure (HF) or death in patients with atrial fibrillation (AF). Hypothesis Soluble ST2 (sST2) may be a good biomarker for the prediction of HF or death in patients with AF. Methods This is a prospective study of patients with nonvalvular AF. Clinical outcomes were HF or death. Clinical and laboratory data were compared between those with and without clinical outcomes. Univariate and multivariate analysis was performed to determine whether sST2 is an independent predictor for heart failure or death in patients with nonvalvular AF. Results A total of 185 patients (mean age: 68.9 ± 11.0 years) were included, 116 (62.7%) were male. The average sST2 and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) levels were 31.3 ± 19.7 ng/ml and 2399.5 ± 6853.0 pg/ml, respectively. Best receiver operating characteristic (ROC) cut off of sST2 for predicting HF or death was 30.14 ng/ml. Seventy‐three (39.5%) patients had an sST2 level ≥30.14 ng/ml, and 112 (60.5%) had an sST2 level